Visual Abstract Summary for the STOPDAPT-2 ACS Trial Question Is 1–2 months of dual antiplatelet therapy (DAPT) followed by clopidogrel monotherapy noninferior to 12 months of DAPT with aspirin and clopidogrel in patients with acute coronary syndromes (ACS)? Design Key … Read More
clopidogrel
OPT-BIRISK Trial: Clopidogrel Monotherapy in High Risk ACS
Trial Title: OPT-BIRISKStudy Type: Multicenter, double-blind, randomized trial Objective: To determine if extended P2Y12 inhibitor monotherapy with clopidogrel is superior to ongoing dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after 9 to 12 months of DAPT after PCI in … Read More
CURRENT-OASIS 7: Double Dose Clopidogrel or ASA in ACS
Year: 2010 Title: CURRENT-OASIS 7 Subtitle: Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing PCI for ACS Type of Trial: Double-blind, Randomized Factorial Trial Objective: To evaluate whether a higher dosage of clopidogrel with aspirin (two … Read More
ACTIVE W Trial Summary: Clopidogrel + ASA vs. OAC for Atrial Fibrillation
2006 ACTIVE W TRIAL Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation Randomized, open treatment, controlled trial M Objective: Among patients with nonvalvular AF, how does combination aspirin/clopidogrel compare to warfarin in reducing the incidence of stroke, systemic embolism, … Read More
ACTIVE A Trial Summary: Clopidogrel + Aspirin in Atrial Fibrillation
2009 ACTIVE A TRIAL Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation Multicenter, double-blind, parallel-group trial M Objective: To assess if the addition of clopidogrel to aspirin reduces the risk of vascular events compared to aspirin alone … Read More
ISAR-SAFE Trial Summary: 6 vs 12 months of DAPT after DES PCI
2015 ISAR-SAFE TRIAL M A randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting multicentre, double-blind, placebo-controlled, randomized controlled trial Objective: To compare the clinical outcome of 6 months of clopidogrel therapy to 12 … Read More
POPular AGE Trial Summary: Antiplatelet agent in NSTEMI
2020 POPULAR AGE TRIAL Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome multicenter, randomized controlled trial Objective: To evaluate the effectiveness of clopidogrel compared with ticagrelor or prasugrel among patients ≥70 … Read More